サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514009

単純ヘルペスウイルス感染症の世界市場

Herpes Simplex Virus Infections

出版日
ページ情報
英文 269 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
単純ヘルペスウイルス感染症の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 269 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

単純ヘルペスウイルス感染症の世界市場は2030年までに66億米ドルに達する見込み

2023年に50億米ドルと推定される単純ヘルペスウイルス感染症の世界市場は、2023年から2030年にかけてCAGR 4.0%で成長し、2030年には66億米ドルに達すると予測されます。

米国市場は14億米ドル、中国はCAGR 6.6％で成長予測

米国の単純ヘルペスウイルス感染症市場は2023年に14億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに14億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは6.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.1%と3.3%と予測されています。欧州では、ドイツがCAGR 2.6%で成長すると予測されています。

単純ヘルペスウイルス感染症-主要動向と促進要因

単純ヘルペスウイルス（HSV）感染は、2種類の単純ヘルペスウイルスによって引き起こされる：HSV-1とHSV-2です。HSV-1は通常、口唇ヘルペスを引き起こし、口唇周辺の冷え症や熱性水疱を呈するが、HSV-2は主に性器ヘルペスを引き起こし、性器や直腸領域のただれを特徴とします。どちらのタイプのHSVも感染力が強く、感染者の皮膚、唾液、性器分泌液に直接触れることで感染します。初感染後、HSVは体内の神経細胞内で休眠状態にあり、後に再活性化して再発を繰り返すことがあります。このような再活性化は、ストレス、病気、免疫機能の低下など、さまざまな要因によって誘発されます。HSV感染症は一般的に生命を脅かすものではないが、再発性であることや、HSV感染症にまつわる汚名のために、大きな不快感や精神的苦痛をもたらすことがあります。

いくつかの動向と発展がHSV感染の管理と治療に影響を及ぼしています。1つの大きな動向は、アシクロビル、バラシクロビル、ファムシクロビルなどの抗ウイルス薬の使用が増加していることであり、これらは重症度と発生頻度を減少させるのに役立ちます。これらの薬剤は、発症時に服用することで治癒を早め、症状を軽くしたり、抑制療法として再発を予防したりすることができます。もう一つの注目すべき研究開発はHSVワクチンの研究であり、これはウイルスに対する長期的な防御を提供し、感染率を減少させることを目的としています。さらに、診断技術の進歩により、HSV検出の正確さとスピードが向上し、タイムリーで適切な治療が可能となっています。公衆衛生の取り組みもまた、HSVに対する認識を高め、感染を予防するための安全な習慣を促進し、感染に関連するスティグマを軽減する上で重要な役割を果たしています。

HSV感染症治療市場の成長は、いくつかの要因によって牽引されています。抗ウイルス薬製剤の技術的進歩により、治療の有効性と利便性が向上し、より幅広い患者層が治療によりアクセスしやすくなっています。HSV感染症の世界の有病率の上昇は、認知度と診断率の上昇と相まって、効果的な管理ソリューションに対する需要を拡大しています。また、積極的な健康管理に対する消費者の動向や、簡便な市販の治療オプションに対する需要も、市場の成長に寄与しています。さらに、新たな治療薬や潜在的なワクチンの発見を目指した研究開発が進行していることも、大きな成長機会を生み出すと期待されています。政府・非政府組織による資金援助や啓発キャンペーンも、市場拡大をさらに後押ししています。これらの要因を総合すると、HSV感染症治療市場の堅調な成長が促進され、世界的に増加する罹患者のニーズに対応しています。

調査対象企業の例（注目の13社）

  • Admedus Limited
  • Agenus Inc.
  • Aicuris Anti-infective Cures Gmbh
  • Asahi Kasei Corporation
  • Chimerix Inc.
  • Clinigen Group Plc
  • Daewoong Pharmaceutical Co., Ltd.
  • F. Hoffmann-la Roche Ltd.
  • Glaxosmithkline Plc
  • Maruho Co. Ltd.
  • Merck
  • Mylan
  • Novartis
  • Sanofi Pasteur
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6451

Global Herpes Simplex Virus Infections Market to Reach US$6.6 Billion by 2030

The global market for Herpes Simplex Virus Infections estimated at US$5.0 Billion in the year 2023, is expected to reach US$6.6 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 6.6% CAGR

The Herpes Simplex Virus Infections market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Herpes Simplex Virus Infections - Key Trends and Drivers

Herpes Simplex Virus (HSV) infections are caused by two types of herpes simplex viruses: HSV-1 and HSV-2. HSV-1 typically causes oral herpes, which presents as cold sores or fever blisters around the mouth, while HSV-2 primarily causes genital herpes, characterized by sores in the genital or rectal area. Both types of HSV are highly contagious and can be transmitted through direct contact with an infected person’s skin, saliva, or genital secretions. After the initial infection, HSV can remain dormant in the body’s nerve cells and reactivate later, leading to recurrent outbreaks. These reactivations can be triggered by various factors such as stress, illness, or weakened immune function. While HSV infections are generally not life-threatening, they can cause significant discomfort and emotional distress due to their recurrent nature and the stigma associated with them.

Several trends and developments are influencing the management and treatment of HSV infections. One major trend is the increasing use of antiviral medications such as acyclovir, valacyclovir, and famciclovir, which can help reduce the severity and frequency of outbreaks. These medications can be taken during outbreaks to accelerate healing and lessen symptoms or as suppressive therapy to prevent recurrent episodes. Another notable development is the research into HSV vaccines, which aim to provide long-term protection against the virus and reduce transmission rates. Additionally, advancements in diagnostic technologies are improving the accuracy and speed of HSV detection, enabling timely and appropriate treatment. Public health initiatives are also playing a crucial role in raising awareness about HSV, promoting safe practices to prevent transmission, and reducing the stigma associated with the infection.

The growth in the HSV infections treatment market is driven by several factors. Technological advancements in antiviral drug formulations are enhancing the effectiveness and convenience of treatments, making them more accessible to a broader patient population. The rising prevalence of HSV infections worldwide, coupled with increasing awareness and diagnosis rates, is expanding the demand for effective management solutions. Consumer behavior trends towards proactive health management and the demand for convenient, over-the-counter treatment options are also contributing to market growth. Furthermore, ongoing research and development activities aimed at discovering new therapeutic agents and potential vaccines are expected to generate significant growth opportunities. The support from governmental and non-governmental organizations in terms of funding and awareness campaigns is further propelling market expansion. Collectively, these factors are driving robust growth in the HSV infections treatment market, addressing the needs of an increasing number of affected individuals globally.

Select Competitors (Total 13 Featured) -

  • Admedus Limited
  • Agenus Inc.
  • Aicuris Anti-infective Cures Gmbh
  • Asahi Kasei Corporation
  • Chimerix Inc.
  • Clinigen Group Plc
  • Daewoong Pharmaceutical Co., Ltd.
  • F. Hoffmann-la Roche Ltd.
  • Glaxosmithkline Plc
  • Maruho Co. Ltd.
  • Merck
  • Mylan
  • Novartis
  • Sanofi Pasteur
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Herpes Simplex Virus Infections - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Use of Antiviral Medications Propels Growth in HSV Treatment Market
    • Advancements in Diagnostic Technologies Strengthen Business Case for Early Detection
    • Research into HSV Vaccines Expands Addressable Market Opportunity
    • Public Health Initiatives and Awareness Campaigns Drive Adoption of Preventive Measures
    • Rising Prevalence of HSV Infections Spurs Demand for Effective Management Solutions
    • Advancements in Antiviral Drug Formulations Generate Demand for Improved Treatments
    • Increasing Over-the-Counter Treatment Options Expand Market Reach
    • Innovations in Suppressive Therapy Techniques Sustain Growth in HSV Treatment Market
    • Development of Long-Term Protective Vaccines Bodes Well for the Market
    • Advances in Genetic and Molecular Research Expand Opportunities for Novel HSV Treatments
    • Increasing Incidence of Stress and Immunocompromised Conditions Spurs Demand for HSV Management
    • Personalized Medicine and Tailored Therapies Drive Adoption of Customized HSV Treatment Plans
    • Digital Health Solutions and Telemedicine Enhance Access to HSV Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Herpes Simplex Virus Infections Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Herpes Simplex Virus Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Herpes Simplex Virus Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • JAPAN
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CHINA
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • EUROPE
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Herpes Simplex Virus Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Herpes Simplex Virus Infections by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • GERMANY
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for Herpes Simplex Virus Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 32: Asia-Pacific 16-Year Perspective for Herpes Simplex Virus Infections by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • INDIA
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: India Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • LATIN AMERICA
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for Herpes Simplex Virus Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Latin America 16-Year Perspective for Herpes Simplex Virus Infections by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MIDDLE EAST
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for Herpes Simplex Virus Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 54: Middle East 16-Year Perspective for Herpes Simplex Virus Infections by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • AFRICA
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR

IV. COMPETITION